KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Other financing activities (2016 - 2026)

Gilead Sciences filings provide 17 years of Other financing activities readings, the most recent being -$63.0 million for Q4 2025.

  • On a quarterly basis, Other financing activities fell 34.04% to -$63.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$440.0 million, a 56.58% decrease, with the full-year FY2025 number at -$440.0 million, down 56.58% from a year prior.
  • Other financing activities hit -$63.0 million in Q4 2025 for Gilead Sciences, up from -$137.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$6.0 million in Q2 2021 to a low of -$176.0 million in Q1 2025.
  • Median Other financing activities over the past 5 years was -$55.0 million (2024), compared with a mean of -$65.9 million.
  • The widest YoY moves for Other financing activities: up 21.43% in 2021, down 700.0% in 2021.
  • Gilead Sciences' Other financing activities stood at -$11.0 million in 2021, then crashed by 109.09% to -$23.0 million in 2022, then tumbled by 47.83% to -$34.0 million in 2023, then plummeted by 38.24% to -$47.0 million in 2024, then crashed by 34.04% to -$63.0 million in 2025.
  • The last three reported values for Other financing activities were -$63.0 million (Q4 2025), -$137.0 million (Q3 2025), and -$64.0 million (Q2 2025) per Business Quant data.